NAM NK cells - Gamida

Drug Profile

NAM NK cells - Gamida

Alternative Names: NAM-NK Cells; Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

Latest Information Update: 18 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gamida-Cell
  • Developer Gamida-Cell; University of Minnesota
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma; Non-Hodgkin's lymphoma
  • Preclinical Solid tumours

Most Recent Events

  • 18 Jan 2018 9231289 - linked CTP. other info already covered by NCT03019666
  • 18 Oct 2017 Phase-I clinical trials in Multiple myeloma (In adults, In the elderly, In volunteers, Second-line therapy or greater) in USA (Parenteral) (NCT03019666)
  • 18 Oct 2017 Phase-I clinical trials in Non-Hodgkin's lymphoma (In adults, In the elderly, In volunteers, Second-line therapy or greater) in USA (Parenteral) (NCT03019666)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top